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Autoimmune peripheral neuropathies such as Guillain-Barre Syndrome (GBS) and chronic 
inflammatory demyelinating polyneuropathy (CIDP) affect millions of people worldwide. 
Despite significant advances in understanding the pathology, the molecular and cellular 
mechanisms of immune-mediated neuropathies remain elusive. T lymphocytes definitely 
play an important role in disease pathogenesis and CD4+ T cells have been the main 
area of research for decades. This is partly due to the fact that the most frequent animal 
model to study autoimmune peripheral neuropathy is experimental allergic neuritis (EAN). 
As it is induced commonly by immunization with peripheral nerve proteins, EAN is driven 
mainly by CD4+ T cells. However, similarly to what has been reported for patients suf-
fering from multiple sclerosis, a significant body of evidence indicates that CD8+ T cells 
may play a pathogenic role in GBS and CIDP disease development and/or progression. 
Here, we summarize clinical studies pertaining to the presence and potential role of 
CD8+ T cells in autoimmune peripheral neuropathies. We also discuss the findings from 
our most recent studies using a transgenic mouse line (L31 mice) in which the T cell 
co-stimulator molecule B7.2 (CD86) is constitutively expressed in antigen presenting 
cells of the nervous tissues. L31 mice spontaneously develop peripheral neuropathy, 
and CD8+ T cells are found accumulating in peripheral nerves of symptomatic animals. 
Interestingly, depletion of CD4+ T cells accelerates disease onset and increases disease 
prevalence. Finally, we point out some unanswered questions for future research to 
dissect the critical roles of CD8+ T cells in autoimmune peripheral neuropathies.
Keywords: Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, cD8 t cells, 
macrophages, cytokines, co-stimulatory molecules, animal models
iNtrODUctiON
Autoimmune peripheral neuropathy, in the broadest sense, refers to a range of clinical syndromes 
mediated by aberrant immune response against self-antigens derived from peripheral nervous tis-
sues including motor, sensory, and autonomic nerves. Guillain-Barré Syndrome (GBS) and chronic 
inflammatory demyelinating polyneuropathy (CIDP) are prototypical autoimmune peripheral 
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neuropathies. The common incidence is about 1.6/100,000/year 
with a prevalence of 6–8.9/100,000 (1, 2). Clinically, GBS and 
CIDP patients present weakness, areflexia, and sensory deficits. 
Characterized by an acute and sudden onset, GBS is the most 
common cause of acute flaccid paralysis and represents a serious 
neurological emergency with 4% of GBS patients dying within the 
first year (3). CIDP is characterized by either chronic progressive, 
stepwise progressive, or relapsing weakness (1, 4). Although the 
majority of CIDP patients initially improve with immunosup-
pressive treatment, the relapse rate is about 50% (5). Over the 
last three decades, even with improved therapeutic options, both 
diseases still carry a severe prognosis as they are associated with 
significant mortality and sustained disability with 28% of patients 
requiring an assistive device to ambulate (6). The pathological 
changes in GBS and CIDP patients are characterized by inflamma-
tory infiltration of both T cells and macrophages into peripheral 
nerves, as well as areas of demyelination, with or without axonal 
damage in peripheral nervous system (PNS) (4, 7).
Both humoral and cellular immune responses against antigen 
epitopes of Schwann cells, myelin and/or axons have been postu-
lated to be responsible for autoimmune peripheral neuropathy. 
However, the extent and the details of the cascade leading to the 
peripheral nervous system damage are incompletely defined. 
Apart from the humoral immune response, T cells play a 
decisive role in the pathogenic sequence of immune-mediated 
nerve damage. Activated CD4+ T cells may operate by recruit-
ing macrophages to exert damage on peripheral nerve tissue or 
may help B cells to produce antibodies against peripheral nerve 
components, thereby inducing complement activation. In addi-
tion to mediating local inflammatory response as CD4+ T cells 
do, activated CD8+ T cells, acting as cytotoxic effector cells, can 
contribute directly to the damage of both myelin and axons.
From recent research, CD8+ T cells emerged as important 
players in multiple sclerosis (MS) pathogenesis. Increasing 
evidence indicates that CD8+ T cells predominate and outnum-
ber CD4+ T cells in all MS lesions, regardless of disease stages 
(8). Furthermore, depletion of CD4+ T cells did not show any 
therapeutic effect in MS patients (9), but when all T cells were 
targeted, a significant reduction in MS relapse was observed 
(10). In fact, infiltration of nervous tissues by CD8+ T cells has 
been observed in various classical neurodegenerative disorders, 
such Amyotrophic Lateral Sclerosis, Alzheimer disease, and 
Parkinson’s disease (11–13). However, due to the rare incidence 
of the diseases and the shortage of appropriate animal models, 
our understanding on the relative contribution of CD4+ and 
CD8+ T cells in the pathogenesis of GBS and CIDP is very much 
limited. Because experimental allergic neuritis (EAN), the most 
used animal model for the study of autoimmune peripheral 
neuropathy, is driven mainly by CD4+ T cells (14, 15), CD4+ 
T cells have been the main area of research for decades. In this 
perspective article, we will summarize clinical studies pertaining 
to the presence and potential role of CD8+ T cells in autoim-
mune peripheral neuropathy. We will also discuss the findings 
from various current available animal models. Emphasis will be 
given to our most recent studies using B7.2 transgenic (L31) mice 
where animals develop spontaneous autoimmune peripheral 
neuropathy and CD8+ T cells are the major players (16). L31 
mice provide a unique opportunity to investigate underlying 
mechanisms of CD8+ T cell-mediated autoimmune peripheral 
neuropathy.
PUtAtive reLevANce OF cD8+ t ceLLs 
iN AUtOiMMUNe PeriPHerAL 
NeUrOPAtHY: eviDeNce FrOM GBs 
AND ciDP PAtieNts
In humans, two-thirds of GBS are preceded by infections with 
viruses or bacteria especially cytomegalovirus (CMV) and 
Campylobacter jejuni (17, 18). Although not as frequent as 
in GBS, the onset and the relapse of CIDP can also be trig-
gered by infections or immunization (5, 19). Biochemical and 
histopathological evidence suggests the potential involvement 
of T cells in the pathogenesis of these autoimmune peripheral 
neuropathies. The levels of soluble interleukin-2 receptors (20) 
and the frequencies of activated T cells were elevated in the 
serum of GBS (21) and CIDP (22) patients. Multifocal infil-
tration of lymphocytes were also found in post mortem and 
biopsy specimens of most GBS and CIDP cases (23). However, 
the specific targets and actors (CD4+ and/or CD8+ T cells) of the 
immune response remain uncertain. Although some discrepan-
cies exist, several data imply putative relevance of CD8+ T cells 
in the pathogenesis of autoimmune peripheral neuropathies. 
For instance, the mean proportion of CD8+ T cells significanly 
increased in the blood GBS patients compared to the control 
group of healthy donors (24); CD8+ T cells were found to out-
number CD4+ T cells at the lesion sites of CIDP (25) and GBS 
(26) patients. Interestingly, Sindern et al. (27) revealed that the 
composition of the T cell subpopulations in the blood of GBS 
patients depends in particular on the nature of the proceed-
ing infection. They found that in GBS patients with evidence 
of recent CMV infection, the proportion of CD8+ T cells were 
abnormally high whereas the proportion of CD4+ T cells were 
abnormally low; in contrast, CD8+ T cells were abnormally 
low in GBS patients with evidence of C. jejuni infection. 
Furthermore, they reported an increase of activated cytotoxic/
suppressor T cells (CD8+CD38+) in progressive and plateau 
phases of GBS, which was normalized in the recovery phase. 
More direct evidence in supporting pathogenic contribution 
of CD8+ T cells in CIDP was provided by two recent studies. 
Mausberg et  al. (28) reported that CD8+ T cells exhibited a 
much broader clonal activation pattern than CD4+ T cells in 
the blood of CIDP patients. In addition, IVIg treatment, which 
was beneficial to patients, normalized the distorted CD8+ T 
cell repertoire and reduced the number of highly activated Vβ 
elements within the CD8+ T cell population. Another study by 
Schneider-Hohendorf et al. (29) reported that T cells in CIDP 
biopsies showed strong monoclonal and oligoclonal restrictions 
in their T cell repertoire, which were reflected in the patients’ 
blood CD8+ T cell pool. Taken together, these data support the 
hypothesis of an antigen driven, CD8+ T cell-mediated attack 
against nerve tissues, even if the target (antigen) of this immune 
response still remains to be identified.
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cD4+ AND cD8+ t ceLLs iN 
AUtOiMMUNe PeriPHerAL 
NeUrOPAtHY: iNsiGHts FrOM  
ANiMAL MODeLs
cD4+ t cells in eAN and NOD B7.2KO Mice
First described in 1955, EAN can be induced either by immuniza-
tion with myelin peptide or by active transfer of antigen sensitized 
T cells in rats, mice, rabbits, and guinea pigs (14, 15). Many of 
our current knowledge of immune-mediated mechanisms of 
demyelination were primarily based on studying EAN, the ani-
mal model for human GBS and CIDP (30). EAN resembles many 
of the clinical and electrophysiological aspects of human GBS/
CIDP. The pathological hallmark of EAN consists of infiltration 
of peripheral nerves by lymphocytes, predominantly CD4+ T 
cells, and macrophages with segmental demyelination and some 
axonal damage. Previous studies have shown that EAN belongs 
to the group of CD4+ T cell-mediated autoimmune diseases that 
can be transferred to naïve animals by CD4+ P2-reactive T cells 
(31). While EAN has provided valuable information regarding 
immunopathogenic mechanisms, it has been criticized for its 
artificial manipulation resulting in the bias towards CD4+ T 
cells. Development of spontaneous autoimmune peripheral 
neuropathy in B7.2 deficient NOD mice (32) introduced another 
tool for mechanistic studies. The individual role of CD4+ T cells 
vs. CD8+ T cells in the pathogenesis of the disease has been care-
fully investigated. While transfer of purified CD4+ T cells isolated 
from affected animals induced the disease in NOD⋅SCID mice, 
the transfer using preparation of CD4+ T-depleted cells failed 
in triggering the disease (32). On the other hand, spontaneous 
autoimmune neuropathy was rapidly induced in NOD⋅SCID 
mice after transfer of CD8+-depleted preparation from affected 
mice (32). These results highlight the necessary and sufficient role 
of CD4+ T cells in the effector phase of this autoimmune disease 
model.
cD8+ t cells in B7.2 transgenic L31 Mice
We recently established a novel and clinically relevant animal 
model of spontaneous autoimmune peripheral polyneuropathy 
in which CD8+ T cells play a critical role (16). Transgenic mice 
with constitutive expression of the co-stimulator B7.2 were 
originally generated by placing the murine B7.2 cDNA under the 
transcriptional control of a MHC-I promoter and an immuno-
globulin enhancer (33). Among multiple transgenic lines, Line 
31 (L31) mice spontaneously developed neurological symptoms 
at the age of 4–6 months (34). Massive infiltration of CD8+ T cells 
and B7.2 high expression macrophages were found in inflamed 
nerves (16). Deficiency in CD4+ T cell generation accelerated 
disease onset and increased disease prevalence (35).
L31 mice and L31mice deficient in CD4+ T cells (L31/CD4KO) 
exhibit motor and sensory deficits, including weakness and paresis 
of limbs, numbness to mechanical stimuli, and hypersensitivity to 
thermal stimulation. Stereotypic pathological changes, including 
demyelination, axonal damage, and infiltration of CD8+ T cells 
and macrophages were found not only in sciatic nerve of symp-
tomatic L31 mice (Figures 1A,B) but also in cranial nerves, e.g., 
facial (Figure 1C) and trigeminal (Figure 1D) nerves. However, 
it is worth noting that only limited inflammatory reaction and 
demyelination were observed in the spinal cords of diseased 
transgenic mice (16), which is consistent with reports from GBS 
patients (36). In addition, there was no tissue destruction or 
immune cell infiltration in other organs (34). The mechanism by 
which the autoimmune cascade is initiated in L31 mice remains 
elusive. We hypothesize that PNS selectivity could be determined, 
in one hand, by the distribution of B7.2 expression. In this model, 
B7.2 expressed constitutively only on resident microglia and mac-
rophages of the nervous system, but not on APCs of any other 
tissues. We have shown that this B7.2 expression on the nervous 
tissues is an absolute requirement for susceptibility to disease 
development (34). On the other hand, as we detected immune 
infiltrates in pre-symptomatic animals in the DRG and spinal 
roots where the blood nerve barrier is fenestrated under physi-
ological conditions (16), it implies that the virtual absence of the 
barrier in these peripheral nerve structures allows CD8+ T cells, 
during immune patrolling, to encounter resident macrophages 
overexpressing B7.2. The CD8+ T cells are reactivated by PNS self-
antigens presented by resident macrophages. They are responsible 
to initiate PNS antigen specific autoimmune response. Although 
molecular targets for the CD8+ T cells are not fully defined, MHC 
class I is expressed constitutively on rodent Schwann’s cells and 
they are able to activate CD8 T cells (37). MHC class I upregula-
tion has been observed on Schwann’s cells in sural nerves of GBS 
patients (26, 38). We are currently assessing MHC I expression 
by the cellular elements of the peripheral nerves of L31 mice. 
The demonstration of direct contact between T cells and MHC 
class 1–expressing target cells (neurons and/or Schwann’s cells) 
would be a strong evidence for a CD8+ T cell–mediated attack.
In the blood of diseased L31 mice, the ratio of CD8+/CD4+ T 
cells was about five times higher than that in wild type (WT) mice, 
which is mainly due to the significant increase of absolute CD8+ T 
cell numbers in the circulation (Figure 2A). Furthermore, these 
CD8+ T cells exhibited activated phenotypes, as the majority of 
these CD8+ T cells expressed high levels of CD44. A greater part 
circulating CD8+CD44hi T cells exhibited CD62-Llo phenotype 
(Figure  2B) that is different from the small amount of central 
memory CD8+ T cells (CD44hiCD62-Lhi) in the blood of WT lit-
termates, suggesting that CD8+ T cells in symptomatic L31 mice 
had already encountered antigens. The increase of CD8+/CD44hi/
CD122hi population in the blood (Figure 2B) entailed a group of 
effecter CD8+ T cells, while the increase of CD8+/CD44hi/CD122lo 
cell population (Figure  2B) suggested the existence of atypical 
memory CD8+ T cells such as those found during chronic viral 
infections which also exhibit low levels of CD122 expression (39).
In affected sciatic nerves of L31 mice, T cell infiltration was 
skewed strikingly towards CD8+ T cells (Figure  2C). These 
infiltrated CD8+ T cells displayed activated phenotypes charac-
terized by CD62-Llo/CD43hi expression, but did not exhibit high 
levels of CD25, which is usually considered as an early T cell 
activation marker (Figure 2D). Furthermore, the data from the 
diseased nerves of L31/CD4KO revealed a significant increase 
of cytokines (IFNγ, TNF) and chemokines (CXCL9, CXCL10) 
(Figure  2E). These cytokines/chemokines released by CD8+ T 
cells and/or macrophages are essential in promoting recruitment 
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and interactions between different subsets of immune cells. The 
fact that L31 mice deficient in IFNγ receptors were completely 
resistant to disease development (35) supports the require-
ment of IFN-γ, mainly derived from CD8+ T cells in disease 
pathogenesis.
Macrophages are also abundantly accumulating in peripheral 
nerves of symptomatic L31 mice. It remains to determine whether 
FiGUre 1 | Pathological changes in peripheral nerves of L31 mice after disease onset. Immune cell infiltration was revealed by immunohistochemistry 
analysis using antibodies against CD8 and Iba-1 (macrophages), while demyelination and axonal damage were detected with antibodies against PGP9.5 and 
fluoromyelin, respectively. (A) Only few resident macrophages and no CD8+ T cells were detected in sciatic nerves of wild type (WT); there were massive infiltration of 
Iba-1+ macrophages and CD8+ T cells as well as severe demyelination and axonal damage in sciatic (B), facial (c), and trigeminal nerves (D) of symptomatic L31 
mice (L31). Scale bar: 50 μm.
and to what extent these cells are required for disease pathogen-
esis. We are particularly interested in assessing the critical role of 
macrophage phagocytosis in Ag presentation, disease initiation 
and macrophage-associated oxidative burst-mediated damage of 
the nervous tissue. Other mechanisms involving macrophages, 
such as antibody-dependent cell-mediated-cytotoxicity could 
also be of relevance.
FiGUre 2 | t cell phenotypes in symptomatic L31 mice. Flow cytometry analysis revealed that the ratio of CD8+ T cells vs. CD4+ T cells was significantly higher in 
the circulating system of symptomatic L31 mice (L31) by comparing with that in wild type (WT) mice, this enhancement was derived from the dramatically increase of 
CD8+ T cell absolute numbers in the blood of L31 mice (A). CD8+ T cells from the blood of symptomatic L31 mice exhibited memory/effector phenotypes, which were 
determined by CD44hiCD62-LloCD8+, as well as the expression levels of CD122 in CD44hiCD8+ population (B). In parallel, both flow cytometry and 
immunohistochemistry analyses demonstrated that infiltration of T cells in affected sciatic nerves was predominated by CD8+ T cells (c), Scale bar: 50 μm. The majority 
of infiltrated CD8+ T cells have low expression of CD62-L and high expression of CD43, but without the high levels of CD25 expression, which is a typical phenotype of 
activated T cells (D). Cytokine/chemokine expression was analyzed using LUMINEX assay. The results indicated a significantly increase of both pro-inflammatory (IFNγ 
and TNF) and chemokines (CXCL9 and CXCL10) in affected sciatic nerves of symptomatic L31 mice (e). n = 3–4/group, ***p < 0.001; ***p < 0.0001.
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To summarize, the massive infiltration of T cells in diseased 
nervous tissues of L31 mice is CD8+, not CD4+ T cells. CD8+ 
T cells in the blood and in the nerves of diseased L31 display 
memory/effector phenotypes. Lack of T cells prevents disease 
development in L31 mice (34). L31 mice deficient in CD4+ T cells 
have an accelerated disease onset and an increased disease pen-
etrance (35). Interestingly, L31 mice have an increased number of 
Foxp3-expressing CD4+ T cells in their lymphoid organs, which 
display an activated phenotype (unpublished data). Initiation 
of disease requires Ag specific CD8+ T cell activation since L31 
mice with an almost unique TCR specificity expressed by CD8+ 
T cells (L31/OT-1 mice) never developed disease (35). Hence, 
CD8+ T cells arise as key players in disease pathogenesis in L31 
B7.2 transgenic mice. Different from EAN where CD4+ T cells 
are the main culprits in mediating neuropathy, L31 mice provide 
a unique opportunity to investigate the involvement of CD8+ T 
cells in autoimmune peripheral neuropathy. In L31 mice, CD4+ 
T cells may function as regulators in the disease pathogenesis.
LessONs FrOM ANiMAL MODeLs FOr 
HUMAN AUtOiMMUNe PeriPHerAL 
NeUrOPAtHY
Whether induced or spontaneous, no single animal model 
perfectly mimics a human disease. These models represent 
only particular aspects of a complex human autoimmune 
disease, and not all animal response patterns are replicated in 
the human immune system. Among the most frequently used 
animal models of autoimmune peripheral neuropathy that we 
discussed above, EAN and NOD B7.2KO mice have provided 
valuable information in the principles of CD4+ T cell-mediated 
autoimmunity and in the development of clinically applicable 
immunotherapies. However, caution should be taken in the 
interpretation of results, especially, EAN, which is induced 
using complete Freund’s adjuvant. L31 mice offer a unique and 
excellent tool to investigate CD8+ T cell-mediated spontaneous 
autoimmmune neuropathy. As epidemiological studies have 
provided strong evidence on the involvement of viral infection 
in the onset of GBS and CIDP, this model might be essential in 
elucidating their viral etiology. However, L31 mice do not recover 
without intervention, suggesting this model is not appropriate 
for examining the mechanism of self-recovery in GBS patients. 
On the whole, autoimmune peripheral neuropathy is neither a 
single disease nor a disease stemming from one etiology; instead 
these are syndromes with multiple variants and very complex 
mechanisms. Thus, while recognizing the limitations of extrapo-
lating findings from each animal model to human disease, what 
is important is the integration of the diverse data generated from 
different models into coherent framework for understanding the 
entirety of autoimmune peripheral neuropathy.
FUtUre DirectiONs: QUestiONs  
NeeD tO Be ADDresseD
Although the potential contribution of CD8+ T cells in autoim-
mune neuropathy, including MS, GBS, and CIDP, has brought 
considerable attention in recent years, our knowledge on CD8+ 
T cells is still very much limited. Why do so many people have 
viral or bacterial infections, but only a small population develop 
GBS/CIDP? Where is the site of the abnormality that initiates 
the disease process? What are the key molecules or cells that 
determine the fate of the disease? Why do some patients recover 
spontaneously, while others do not? Whether and to what extent 
CD8+ T cells are engaged in different stages of the diseases, and 
whether CD8+ T cells can be targeted for disease prevention and 
effective treatment? Use of appropriate animal models should 
help answer these questions and decipher the role of CD8+ T cells 
in human autoimmune peripheral neuropathy.
stAteMeNt ON ANiMAL etHics
All experiments were in accordance with the guidelines of the 
Canadian Council on Animal Care, and approved by the animal 
care committee of McGill University (Permit #5533).
AcKNOWLeDGMeNts
MY is supported by the CIHR Neuroinflammation Training 
Program. This work was supported by funding from the Canadian 
Institutes for Health Research (CIHR) MOP-111129 to JZ and 
from Multiple Sclerosis Society of Canada to SF.
reFereNces
1. Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneu-
ropathies. Nat Rev Neurol (2014) 10(8):435–46. doi:10.1038/nrneurol.2014.117 
2. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology 
of Guillain-Barre syndrome worldwide. A systematic literature review. 
Neuroepidemiology (2009) 32(2):150–63. doi:10.1159/000184748 
3. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet (2005) 
366(9497):1653–66. doi:10.1016/S0140-6736(05)67665-9 
4. Dalakas MC. Medscape. Advances in the diagnosis, pathogenesis and 
treatment of CIDP. Nat Rev Neurol (2011) 7(9):507–17. doi:10.1038/
nrneurol.2011.121 
5. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory 
demyelinating polyradiculoneuropathy. Clinical characteristics, course, and 
recommendations for diagnostic criteria. Arch Neurol (1989) 46(8):878–84. 
doi:10.1001/archneur.1989.00520440064022 
6. Dimachkie MM, Barohn RJ, Katz J. Multifocal motor neuropathy, multifocal 
acquired demyelinating sensory and motor neuropathy, and other chronic 
acquired demyelinating polyneuropathy variants. Neurol Clin (2013) 
31(2):533–55. doi:10.1016/j.ncl.2013.01.001 
7. Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med (2012) 
366(24):2294–304. doi:10.1056/NEJMra1114525 
8. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. 
Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active 
multiple sclerosis lesions as shown by micromanipulation and single cell 
polymerase chain reaction. J Exp Med (2000) 192(3):393–404. doi:10.1084/
jem.192.3.393 
9. van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, 
et  al. Treatment of multiple sclerosis with the monoclonal anti-CD4 anti-
body cM-T412: results of a randomized, double-blind, placebo-controlled, 
MR-monitored phase II trial. Neurology (1997) 49(2):351–7. 
10. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. 
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 
(2008) 359(17):1786–801. doi:10.1056/NEJMoa0802670 
11. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, et al. 
T lymphocytes potentiate endogenous neuroprotective inflammation in 
October 2015 | Volume 6 | Article 5327
Yang et al. CD8+ T cells and autoimmune peripheral neuropathy
Frontiers in Immunology | www.frontiersin.org
a mouse model of ALS. Proc Natl Acad Sci USA (2008) 105(46):17913–8. 
doi:10.1073/pnas.0804610105 
12. Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer’s disease. 
Neuromolecular Med (2005) 7(3):255–64. doi:10.1385/NMM:7:3:255 
13. Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and 
leucocyte common antigen positive cells in Alzheimer’s disease brain tissue. 
Neurosci Lett (1988) 91(3):259–64. doi:10.1016/0304-3940(88)90690-8 
14. Waksman BH, Adams RD. Allergic neuritis: an experimental disease of rabbits 
induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 
(1955) 102(2):213–36. doi:10.1084/jem.102.2.213 
15. Brostoff SW, Levit S, Powers JM. Induction of experimental allergic neuritis 
with a peptide from myelin P2 basic protein. Nature (1977) 268(5622):752–3. 
doi:10.1038/268752a0 
16. Yang M, Rainone A, Shi XQ, Fournier S, Zhang J. A new animal model 
of spontaneous autoimmune peripheral polyneuropathy: implications 
for Guillain-Barre syndrome. Acta Neuropathol Commun (2014) 2(1):5. 
doi:10.1186/2051-5960-2-5 
17. Poropatich KO, Walker CL, Black RE. Quantifying the association between 
Campylobacter infection and Guillain-Barre syndrome: a systematic review. J 
Health Popul Nutr (2010) 28(6):545–52. doi:10.3329/jhpn.v28i6.6602 
18. Hadden RD, Gregson NA. Guillain–Barre syndrome and Campylobacter 
jejuni infection. Symp Ser Soc Appl Microbiol (2001) 30:145S–54S. 
doi:10.1046/j.1365-2672.2001.01363.x 
19. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. 
Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J 
Peripher Nerv Syst (2009) 14(4):310–5. doi:10.1111/j.1529-8027.2009.00243.x 
20. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 
concentrations in Guillain-Barre syndrome and chronic idiopathic demy-
elinating polyradiculoneuropathy: comparison with other neurological 
diseases of presumed immunopathogenesis. Ann Neurol (1991) 30(1):48–53. 
doi:10.1002/ana.410300110 
21. Van den Berg LH, Mollee I, Wokke JH, Logtenberg T. Increased frequencies of 
HPRT mutant T lymphocytes in patients with Guillain-Barre syndrome and 
chronic inflammatory demyelinating polyneuropathy: further evidence for a 
role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J 
Neuroimmunol (1995) 58(1):37–42. doi:10.1016/0165-5728(94)00185-Q 
22. Klehmet J, Staudt M, Ulm L, Unterwalder N, Meisel A, Meisel C. Circulating 
lymphocyte and T memory subsets in glucocorticosteroid versus IVIG 
treated patients with CIDP. J Neuroimmunol (2015) 283:17–22. doi:10.1016/j.
jneuroim.2015.03.023 
23. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory 
infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic 
inflammatory demyelinating neuropathy. Muscle Nerve (1996) 19(4):474–87. 
doi:10.1002/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9 
24. Dahle C, Vrethem M, Ernerudh J. T lymphocyte subset abnormalities 
in peripheral blood from patients with the Guillain-Barre syndrome. J 
Neuroimmunol (1994) 53(2):219–25. doi:10.1016/0165-5728(94)90032-9 
25. Matsumuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory 
demyelinating polyneuropathy: histological and immunopathological 
studies on biopsied sural nerves. J Neurol Sci (1994) 127(2):170–8. 
doi:10.1016/0022-510X(94)90070-1 
26. Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern 
of complement activation and cytotoxic T cell response in Guillain-Barre 
syndrome. Brain (2003) 126(Pt 9):2034–42. doi:10.1093/brain/awg207 
27. Sindern E, Oreja-Guevara C, Raulf-Heimsoth M, Baur X, Malin JP. A longitu-
dinal study of circulating lymphocyte subsets in the peripheral blood during 
the acute stage of Guillain-Barre syndrome. J Neurol Sci (1997) 151(1):29–34. 
doi:10.1016/S0022-510X(97)00082-8 
28. Mausberg AK, Dorok M, Stettner M, Muller M, Hartung HP, Dehmel T, et al. 
Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology 
(2013) 80(3):296–303. doi:10.1212/WNL.0b013e31827debad 
29. Schneider-Hohendorf T, Schwab N, Uceyler N, Gobel K, Sommer C, 
Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating 
polyradiculoneuropathy. Neurology (2012) 78(6):402–8. doi:10.1212/
WNL.0b013e318245d250 
30. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelin-
ating disorders of the nervous system. Mol Med Today (2000) 6(2):88–91. 
doi:10.1016/S1357-4310(99)01639-1 
31. Linington C, Izumo S, Suzuki M, Uyemura K, Meyermann R, Wekerle H. A 
permanent rat T cell line that mediates experimental allergic neuritis in the 
Lewis rat in vivo. J Immunol (1984) 133(4):1946–50. 
32. Salomon B, Rhee L, Bour-Jordan H, Hsin H, Montag A, Soliven B, et  al. 
Development of spontaneous autoimmune peripheral polyneuropathy in 
B7-2-deficient NOD mice. J Exp Med (2001) 194(5):677–84. doi:10.1084/
jem.194.5.677 
33. Fournier S, Rathmell JC, Goodnow CC, Allison JP. T cell-mediated elimina-
tion of B7.2 transgenic B cells. Immunity (1997) 6(3):327–39. doi:10.1016/
S1074-7613(00)80335-0 
34. Zehntner SP, Brisebois M, Tran E, Owens T, Fournier S. Constitutive expression 
of a costimulatory ligand on antigen-presenting cells in the nervous system 
drives demyelinating disease. FASEB J (2003) 17(13):1910–2. doi:10.1096/
fj.03-0199fje
35. Brisebois M, Zehntner SP, Estrada J, Owens T, Fournier S. A pathogenic role 
for CD8+ T cells in a spontaneous model of demyelinating disease. J Immunol 
(2006) 177(4):2403–11. doi:10.4049/jimmunol.177.4.2403 
36. Gachter C, Petersen JA, Schwarz U, Pangalu A, Tarnutzer AA. 
Teaching NeuroImages: variant of Guillain-Barre syndrome with 
spinal cord involvement. Neurology (2015) 84(5):e30. doi:10.1212/
WNL.0000000000001217 
37. Meyer zu Horste G, Heidenreich H, Mausberg AK, Lehmann HC, ten 
Asbroek AL, Saavedra JT, et al. Mouse Schwann cells activate MHC class I 
and II restricted T-cell responses, but require external peptide processing for 
MHC class II presentation. Neurobiol Dis (2010) 37(2):483–90. doi:10.1016/j.
nbd.2009.11.006 
38. Meyer Zu Horste G, Heidenreich H, Lehmann HC, Ferrone S, Hartung HP, 
Wiendl H, et al. Expression of antigen processing and presenting molecules 
by Schwann cells in inflammatory neuropathies. Glia (2010) 58(1):80–92. 
doi:10.1002/glia.20903 
39. Boyman O, Letourneau S, Krieg C, Sprent J. Homeostatic proliferation and 
survival of naive and memory T cells. Eur J Immunol (2009) 39(8):2088–94. 
doi:10.1002/eji.200939444 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Yang, Peyret, Shi, Siron, Jang, Wu, Fournier and Zhang. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
